Notice NOT-NR-23-012 from the NIH Guide for Grants and Contracts

£36,572 - £44,722 (Grade 4): Barts Cancer Institute , Queen Mary University London: A postdoctoral research position is available to investigate the epigenetic mechanisms operating at the boundary between normal and cancer in an in... London, Greater London, England

Notice NOT-NS-23-094 from the NIH Guide for Grants and Contracts

Notice NOT-HD-23-019 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-097 from the NIH Guide for Grants and Contracts

Negotiable: Oxford Nanopore Technologies: This exciting and challenging role will work within the Customer Analysis Workflows group specialising in clinical bioinformatics to maintain a coherent set of analysis software tools for clinical end users of ONT's sequencing platforms through OND with a Oxford, England

£34,000 to £39,000 per annum: Rothamsted Research: Are you a talented Machine Learning Bioinformatician with a passion for advancing the field of bioinformatics? We are seeking a skilled individual ... Harpenden, Hertfordshire

Funding Opportunity RFA-NS-24-014 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint R25 program is to encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and clinical research workforce, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Mentoring Activities.The fully integrated educational activities should prepare undergraduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that either: 1) have a historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation NSF, see http://www.nsf.gov/statistics/wmpd/) (i.e., African Americans or Blacks, Hispanic or Latino Americans, American Indians, Alaska Natives, Native Hawaiians, U.S. Pacific Islanders, and persons with disabilities) or 2) have a documented track record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), which has resulted in increasing the institution's contribution to the national pool of graduates from underrepresented backgrounds who pursue biomedical research careers; b) a research-intensive institution that has an established neuroscience or neuroscience-related program; c) integrated

Notice NOT-AT-24-011 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-100 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-246 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize mechanistic studies toward fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. These studies should be performed in context of research concerning the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is outside of the scope of this NOFO.

All of these skills can be acquired through a science heavy degree. The candidate will provide critical support for the laboratory that includes the following…
From Medical College of Wisconsin - Thu, 20 Jul 2023 15:09:03 GMT - View all Milwaukee, WI jobs

Perform immunology experiments from design conception to final data analysis and presentation of results. Oversee organization, coding, synthesis, and analysis…
From Medical College of Wisconsin - Thu, 20 Jul 2023 15:08:46 GMT - View all Milwaukee, WI jobs

From £41,935 with benefits, subject to skills and experience: The Francis Crick Institute: This grant-funded role will enable a researcher to use the mouse gastruloid system as an in vitro model of PGC development London (Central), London (Greater)

Notice NOT-GM-23-050 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-365 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AT-24-004 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial and/or implementation science Demonstration Projects within the infrastructure of the NIH-DoD-VA Pain Management Collaboratory (PMC) on nonpharmacologic approaches to pain management and other comorbid conditions in U.S. veterans, military personnel, and their families. The PMC established a Coordinating Center that provides national leadership and technical expertise for all aspects of health care system (HCS)-focused research including assistance to UG3/UH3 grant awardees.

Funding Opportunity RFA-HL-24-009 from the NIH Guide for Grants and Contracts. This NOFO will support preliminary studies aimed to obtain information necessary to guide the design of a full randomized control trial to test whether sleep and circadian targeted interventions improve the clinical course and treatment outcomes in individuals with Type 1 Diabetes (T1D). Applications should focus on pilot studies to inform practical and potentially sustainable strategies to improve processes of care and cardiometabolic health outcomes in individuals with T1D. The scope of research for this NOFO includes a range of feasibility metrics (e.g., optimizing recruitment, retention, randomization); intervention logistics (e.g., determine independent variable(s), dose-response, duration); study design/statistical considerations (e.g., determination of effect size, sample size, and statistical power; inclusion/exclusion criteria, control variables); adherence outcomes (measures of patient acceptance of, satisfaction with, and adherence to treatment); assessment of intermediate markers of the intervention (e.g. glycemic control, vascular dysfunction, inflammation, and/or neuroendocrine and metabolic function); and selection of primary and/or secondary outcome(s) measures. Ultimately, results from these pilot studies will be used to develop a well-powered, evidence-based definitive clinical trial that could improve clinical care and cardiometabolic outcomes in individuals with T1D and to inform guidelines for this patient population. Transdisciplinary investigative teams including relevant expertise in sleep/circadian, T1D and cardiovascular research, as well as needed expertise in clinical trial design, biostatistics and other appropriate areas are encouraged. Studies should include active participation of children, adolescents, and/or adults with T1D. This program is not intended to develop or validate new treatments of devices for sleep and/or circadian deficiency. Animal studies will not be considered responsive to this initiative.

Funding Opportunity RFA-HL-24-008 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to elucidate the contribution of sleep deficiency and circadian disruption to metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in individuals living with Type 1 Diabetes (T1D). The RFA will support clinically relevant, mechanism focused research on the interface between sleep, circadian rhythms biology, T1D and cardiovascular disease. Multi-disciplinary teams bridging sleep/circadian, diabetes, and cardiovascular research are encouraged. Proposed research should be relevant to the ultimate goal of applying sleep and circadian strategies to improve treatment and outcomes in individuals with T1D, and to mitigate related cardiovascular complications. Observational studies, epidemiology, efficacy trials and basic animal research will not be responsive to this NOFO.

£25,000+ +Endless Opportunity + Profit Share: YouSeq: An exciting role with a primary focus on Next Generation Sequencing technologies Winchester, Hampshire